(18 August 2014, Philadephia, PA) – The Intellectual Property and Science business of Thomson Reuters, the world leader in intelligent information for businesses and professionals, released a comprehensive disease profile on ebola virus disease that includes a detailed analysis of two new treatments in the pipeline and two experimental candidates approaching development.
The Thomson Reuters Ebola Disease Briefing is available free of charge through its LS Research website, a resource providing researchers with the latest news on disease insights and developing treatments, through reports and biological pathway maps. This resource offers disease profiling and comparative data to the current drug landscape for clinically devastating, relevant diseases, such as ebola.
Read the detailed press release.
